Should You Buy Moderna Inc (MRNA) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
Not a good buy right now for an impatient buyer. The chart is still bullish on moving averages, but momentum is fading and the stock is trading well above most recent Wall Street price targets (many in the $24–$34 range). With hedge funds selling aggressively and fundamentals still contracting, the risk/reward at ~$45–$47 looks unfavorable for an immediate entry.
Technical Analysis
Pre-market: $45.71 (-2.45%), under the pivot (46.823), which suggests near-term weakness unless it reclaims that level quickly.
Trend: Bullish MA stack (SMA_5 > SMA_20 > SMA_200) indicates the broader trend has turned up.
Momentum: MACD histogram is positive (0.287) but “positively contracting,” implying upside momentum is weakening rather than accelerating.
RSI: RSI_6 at ~61 is neutral-to-slightly-warm; not oversold and not offering a “discount” entry.
Key levels: Support S1 ~40.73 (then S2 ~36.97). Resistance R1 ~52.92 (then R2 ~56.68). With price below pivot, the more attractive technical entry would typically be closer to support (~41) or after a clean reclaim/hold above pivot and a push toward ~$52.9.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent trend: Ratings/targets have drifted more cautious. UBS downgraded to Neutral (PT $34 from $40). BofA stayed Underperform (PT raised slightly to $24 from $21). Morgan Stanley maintained Equal Weight (PT $28 from $30). Jefferies initiated Hold ($30). Barclays initiated Equal Weight with a very low $25 PT. Piper remains a notable bullish outlier with Overweight and a much higher $63 PT.
Wall Street pros: Platform/pipeline optionality (esp. oncology and next-gen respiratory products) + cost cuts + potential biotech-tailwind setup in 2026.
Wall Street cons: Low visibility on durable growth and timing to break-even/profitability (some skepticism vs company guidance), and pipeline outcomes (e.g., cancer vaccine) viewed as binary. Net: Street is mostly cautious/neutral-to-negative at current prices.
Wall Street analysts forecast MRNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 29.36 USD with a low forecast of 17 USD and a high forecast of 63 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast MRNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 29.36 USD with a low forecast of 17 USD and a high forecast of 63 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 45.300
Current: 45.300
